Provided by Tiger Fintech (Singapore) Pte. Ltd.

Anaptysbio Inc

18.40
-0.1900-1.02%
Post-market: 18.400.00000.00%19:54 EDT
Volume:875.44K
Turnover:15.96M
Market Cap:564.27M
PE:-3.60
High:18.65
Open:18.55
Low:17.35
Close:18.59
Loading ...

Is AnaptysBio (ANAB) Stock Outpacing Its Medical Peers This Year?

Zacks
·
13 Feb

AnaptysBio (ANAB) Surges 30.5%: Is This an Indication of Further Gains?

Zacks
·
13 Feb

AnaptysBio price target raised to $22 from $19 at H.C. Wainwright

TIPRANKS
·
13 Feb

BUZZ-AnaptysBio climbs on arthritis drug trial data

Reuters
·
12 Feb

Truist says AnaptysBio handing of placebo ‘raise doubt’ about Phase 2 RA data

TIPRANKS
·
12 Feb

AnaptysBio Shares Surge 37% After Mid-Stage Rheumatoid Arthritis Trial Meets Primary Goal

Dow Jones
·
12 Feb

AnaptysBio's Rheumatorid Arthritis Drug Meets Primary Endpoint in Phase 2 Trial; Shares Rise

MT Newswires Live
·
12 Feb

BRIEF-Anaptys Announces Rosnilimab Achieved Positive Results In RA Phase 2B Trial

Reuters
·
12 Feb

AnaptysBio Inc - Rosinilimab Safe and Well Tolerated With Similar Adverse Event Rates VS Placebo

THOMSON REUTERS
·
12 Feb

AnaptysBio Inc - Rosinilimab Achieves Statistical Significance on Key Secondary Endpoints at Week 12

THOMSON REUTERS
·
12 Feb

AnaptysBio Inc - Top-Line Week 12 Phase 2 Ulcerative Colitis Data for Rosnilimab Expected in Q4 2025

THOMSON REUTERS
·
12 Feb

Anaptys Announces Rosnilimab Achieved Positive Results in Ra Phase 2B Trial and Highest Ever Reported Cdai Lda Response Over 6 Months

THOMSON REUTERS
·
12 Feb

BRIEF-Anaptys To Announce Top-Line Data From Phase 2B Trial Of Rosnilimab, A PD-1 Depleter And Agonist, In Rheumatoid Arthritis

Reuters
·
12 Feb

Anaptys to Announce Top-Line Data From Phase 2B Trial of Rosnilimab, a Pd-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025

THOMSON REUTERS
·
12 Feb

Wedbush Sticks to Its Buy Rating for AnaptysBio (ANAB)

TIPRANKS
·
07 Feb

Shareholders in AnaptysBio (NASDAQ:ANAB) are in the red if they invested three years ago

Simply Wall St.
·
05 Feb